These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35582530)

  • 1. Emerging mechanisms of immunotherapy resistance in sarcomas.
    Florou V; Wilky BA
    Cancer Drug Resist; 2022; 5(1):199-213. PubMed ID: 35582530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Trends in Immunotherapy for Adult Sarcomas.
    Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
    Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
    Seong G; D'Angelo SP
    Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and Biomarkers in Sarcoma.
    Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
    Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
    Chew HY; Chan V; Simpson F; Dolcetti R
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
    Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic strategies for sarcoma: current perspectives.
    Li X; Wang G; Cai Z; Sun W
    Am J Transl Res; 2020; 12(12):7693-7701. PubMed ID: 33437354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
    van Oost S; Meijer DM; Kuijjer ML; Bovée JVMG; de Miranda NFCC
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
    Fazel M; Dufresne A; Vanacker H; Waissi W; Blay JY; Brahmi M
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
    Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
    Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the landscape of immunotherapy approaches in sarcomas.
    Pilavaki P; Panagi M; Arifi S; Jones RL; Stylianopoulos T; Constantinidou A
    Front Oncol; 2022; 12():1069963. PubMed ID: 36686827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional.
    Borgatti A; Dickerson EB; Lawrence J
    Vet Comp Oncol; 2020 Mar; 18(1):9-24. PubMed ID: 31749286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
    Ozaniak A; Vachtenheim J; Lischke R; Bartunkova J; Strizova Z
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.